A phase I clinical trial of low-dose interferon-α-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma

By Amato Robert   Khan Muhammad  

Cancer Chemotherapy and Pharmacology, Vol. 61, Iss. 6, 2008-05 ,pp. : 1069-1073

Springer Publishing Company

Access to resources Recommend Favorite

Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma

By Bennouna Jaafar   Bompas Emmanuelle   Neidhardt Eve   Rolland Frédéric   Philip Irène   Galéa Céline   Salot Samuel   Saiagh Soraya   Audrain Marie   Rimbert Marie   Lafaye-de Micheaux Sylvie   Tiollier Jérôme   Négrier Sylvie  

Cancer Immunology, Immunotherapy, Vol. 57, Iss. 11, 2008-11 ,pp. : 1599-1609

Springer Publishing Company

Access to resources Recommend Favorite

A Phase II Trial of Panobinostat, a Histone Deacetylase Inhibitor, in the Treatment of Patients with Refractory Metastatic Renal Cell Carcinoma

By Hainsworth John D.   Infante Jeffrey R.   Spigel David R.   Arrowsmith Edward R.   Boccia Ralph V.   Burris Howard A.  

Cancer Investigation, Vol. 29, Iss. 7, 2011-07 ,pp. : 451-455

Informa Healthcare

Access to resources Recommend Favorite

An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma

By Naito Seiji   Tsukamoto Taiji   Usami Michiyuki   Fujimoto Hiroyuki   Akaza Hideyuki  

Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 6, 2010-11 ,pp. : 1065-1070

Springer Publishing Company

Access to resources Recommend Favorite

Health-related quality of life in Japanese patients with metastatic renal cell carcinoma treated with sunitinib

By Miyake Hideaki  

International Journal of Clinical Oncology, Vol. 18, Iss. 2, 2013-04 ,pp. : 220-225

Springer Publishing Company

Access to resources Recommend Favorite